Figure 1.

Citrullinated peptide combination vaccination provides poor tumour therapy in HLA-DP4 transgenic mice. HLA-DP4 transgenic mice were challenged with B16 cells constitutively expressing DP4 (A) or expressing DP4 under an IFNγ inducible promoter (B) and four days later mice were immunised with combination of 10ug each of seven eluted peptides and tumour growth and survival monitored. N=10/group. (C), HLA-DP4 transgenic mice were immunised with seven peptide combination vaccine at days 1, 8 and 15 and immune responses monitored at day 21 by IFNγ ELISpot assay. Results are representative of at least two independent experiments in which n=3. (D), Competition of equal quantity of non-biotinylated competitor peptides in the presence of 10µg biotinylated HepB 181-193 peptide. Results are representative of at least two independent experiments.